

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

PRODUCT INFORMATION



Buparvaguone

Item No. 21704

CAS Registry No.:	88426-33-9
Formal Name:	2-[[4-(1,1-dimethylethyl)
_	cyclohexyl]methyl]-3-hydroxy-1,4- naphthalenedione
Synonym:	BW 720C
MF:	$C_{21}H_{26}O_3$
FW:	326.4 OH
Purity:	≥98%
UV/Vis.:	λ _{max} : 252, 282, 332 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly

Laboratory Procedures

Buparvaquone is supplied as a crystalline solid. A stock solution may be made by dissolving the buparvaguone in the solvent of choice. Buparvaguone is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of buparvaquone in DMSO and DMF is approximately 1 mg/ml. Buparvaquone is also sparingly soluble in ethanol.

Buparvaquone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, buparvaquone should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Buparvaquone has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Buparvaquone is a hydroxynaphthoquinone that inhibits electron transport by blocking cytochrome bc_1 in parasites that cause leishmaniasis.¹ Formulations containing buparvaquone are used to treat theileriosis, an infection by the parasites T. annulata and T. parva (in vitro EC_{50} s of 1.5 x 10⁻⁸ M and 6.1 x 10⁻¹⁰ M, respectively).^{2,3}

References

- 1. Ortiz, D., Forquer, I., Boitz, J., et al. Targeting the cytochrome bc1 complex of Leishmania parasites for discovery of novel drugs. Antimicrob. Agents Chemother. 60(8), 4972-4982 (2016).
- 2. Abdou, T.A., Abou-El-naga, T.R., and Mahmoud, M.A. Clinicopathological studies on Theileria annulata infection in Siwa oasis in Egypt, (2005), 70 in 56th Annual Meeting of the European Association for Animal Production.
- 3. Hudson, A.T., Randall, A.W., Fry, M., et al. Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity. Parasitology 90(Pt 1), 45-55 (1985).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/15/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM